Cell:血管紧张素受体——瞄准人类健康的隐形杀手

2015-04-28 佚名 生物通

每三个美国人中就有一人罹患高血压,这一人类健康的隐形杀手可以导致冠心病、心力衰竭和中风等疾病。利用一种先进的X-射线分析技术,由来自美国、德国的科学家组成的一个研究小组,揭示出了人体中最重要的血压调控因子——血管紧张素受体AT1R的分子结构。他们的研究结果发表在4月23日的《细胞》(Cell)杂志上。南加州大学Dornsife文理学院首席研究员及教授Vadim Cherezov说,这项研究工作有可

每三个美国人中就有一人罹患高血压,这一人类健康的隐形杀手可以导致冠心病、心力衰竭和中风等疾病。利用一种先进的X-射线分析技术,由来自美国、德国的科学家组成的一个研究小组,揭示出了人体中最重要的血压调控因子——血管紧张素受体AT1R的分子结构。他们的研究结果发表在4月23日的《细胞》(Cell)杂志上。



南加州大学Dornsife文理学院首席研究员及教授Vadim Cherezov说,这项研究工作有可能促使快速开发出副作用更小的新药物。

当被血管紧张素激活时,血管紧张素受体AT1R会触动细胞内的两条主要信号通路。一条信号通路由G蛋白(这一蛋白家族起开关作用,可传送信号通过细胞膜)介导,可引起血管收缩导致血压升高。另一条信号通路由抑制蛋白(arrestin)介导,可带来许多的有益影响。

医生经常会开给病人一些血管紧张素受体阻断剂,这些药物关闭了两条信号通路,因此在阻止血管收缩的同时也会导致一些副作用,例如头晕、头痛、嗜睡和血钾水平升高等。

Cherezov说:“这就像用木板来打苍蝇。尽管它确实起作用——但如果能用更精细的方法只阻断G蛋白信号通路,而使另一条信号通路保持活性,或许可以在生成阳性反应的同时避免大量的副作用。为此,你需要准确地了解药物样分子结合这一受体的机制和位置,以及它们造成了什么构象改变。”

研究人员构建出了这一受体与一种血管紧张素受体阻断剂的复合物的晶体。随后,他们借助世界上最强大的X-射线激光器,用强至可以生成衍射图形的能量闪光击中了晶体。通过解读这些衍射图形,科学家们以0.29纳米的分辨率拼合出了AT1R受体的结构——在原子尺度上显示出了药物分子确切的结合位置。

研究的共同作者、德国电子同步辐射装置(Deutsches Elektronen-Synchrotron DESY)自由电子激光科学中心的Cornelius Gati说:“尽管它与医学相关,直到现在这一受体的结构才为人所知。这些数据显示了结合口袋的精确结构,以及与结合的高血压药物之间的互作。它提供了有关作用模式的一些新见解,并将推动开发出新药。”

科学家们说,希望确切地了解这一分子受体的结构可以帮助设计出副作用更小的定制降血压药。“我们的研究工作朝着这一方向迈出了第一步,”Cherezov说。接下来他打算继续研究这一受体以及另一个密切相关的受体。

原始出处:

Haitao Zhang ,Hamiyet Unal,Cornelius Gati,Gye Won Han,et al.Structure of the Angiotensin Receptor Revealed by Serial Femtosecond Crystallography.Cell 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1694517, encodeId=b930169451e4e, content=<a href='/topic/show?id=2dde25041f2' target=_blank style='color:#2F92EE;'>#人类健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25041, encryptionId=2dde25041f2, topicName=人类健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Sep 25 23:55:00 CST 2015, time=2015-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959343, encodeId=0cdc195934380, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jan 19 00:55:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869092, encodeId=2dfa186909228, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 03 20:55:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22367, encodeId=a8632236efe, content=相关研究应该了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Fri May 01 11:45:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589282, encodeId=0e521589282df, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Thu Apr 30 04:55:00 CST 2015, time=2015-04-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1694517, encodeId=b930169451e4e, content=<a href='/topic/show?id=2dde25041f2' target=_blank style='color:#2F92EE;'>#人类健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25041, encryptionId=2dde25041f2, topicName=人类健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Sep 25 23:55:00 CST 2015, time=2015-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959343, encodeId=0cdc195934380, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jan 19 00:55:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869092, encodeId=2dfa186909228, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 03 20:55:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22367, encodeId=a8632236efe, content=相关研究应该了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Fri May 01 11:45:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589282, encodeId=0e521589282df, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Thu Apr 30 04:55:00 CST 2015, time=2015-04-30, status=1, ipAttribution=)]
    2016-01-19 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1694517, encodeId=b930169451e4e, content=<a href='/topic/show?id=2dde25041f2' target=_blank style='color:#2F92EE;'>#人类健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25041, encryptionId=2dde25041f2, topicName=人类健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Sep 25 23:55:00 CST 2015, time=2015-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959343, encodeId=0cdc195934380, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jan 19 00:55:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869092, encodeId=2dfa186909228, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 03 20:55:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22367, encodeId=a8632236efe, content=相关研究应该了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Fri May 01 11:45:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589282, encodeId=0e521589282df, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Thu Apr 30 04:55:00 CST 2015, time=2015-04-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1694517, encodeId=b930169451e4e, content=<a href='/topic/show?id=2dde25041f2' target=_blank style='color:#2F92EE;'>#人类健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25041, encryptionId=2dde25041f2, topicName=人类健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Sep 25 23:55:00 CST 2015, time=2015-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959343, encodeId=0cdc195934380, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jan 19 00:55:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869092, encodeId=2dfa186909228, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 03 20:55:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22367, encodeId=a8632236efe, content=相关研究应该了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Fri May 01 11:45:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589282, encodeId=0e521589282df, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Thu Apr 30 04:55:00 CST 2015, time=2015-04-30, status=1, ipAttribution=)]
    2015-05-01 hbwang006

    相关研究应该了解

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1694517, encodeId=b930169451e4e, content=<a href='/topic/show?id=2dde25041f2' target=_blank style='color:#2F92EE;'>#人类健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25041, encryptionId=2dde25041f2, topicName=人类健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Sep 25 23:55:00 CST 2015, time=2015-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959343, encodeId=0cdc195934380, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jan 19 00:55:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869092, encodeId=2dfa186909228, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 03 20:55:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22367, encodeId=a8632236efe, content=相关研究应该了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Fri May 01 11:45:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589282, encodeId=0e521589282df, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Thu Apr 30 04:55:00 CST 2015, time=2015-04-30, status=1, ipAttribution=)]

相关资讯

JAMA:高血压患者补充叶酸会降低中风的风险

根据发表在JAMA上的一项研究,在中国有超过两万多的成年人患有高血压但没有中风或心脏病史,高血压的药物依那普利和叶酸的结合使用,与单用依那普利相比,显著降低首次卒中的风险。这项研究与发表美在国心脏病学会年度科学会议的演讲不谋而合。 根据文章中的背景信息,中风是中国死亡的首要原因,是世界死亡的第二大原因。初级预防(第一集事前预防)尤为重要,因为约77%的中风是第一事件。由于有限性和不一致的数据,关

SC-ICC2015:孙宁玲--β受体阻滞剂可作为高血压一线治疗药物吗?

2015年4月11日,在第17届中国南方国际心血管病学术会议“合理用药论坛”上,北京大学人民医院孙宁玲教授针对这一问题,以“β受体阻滞剂是否可以作为高血压治疗一线药物——国际指南引发β受体阻滞剂争议”为题,对这一重要问题做了详细诠释。关于β受体阻滞剂在高血压治疗中的地位问题,近些年一直存在较大争议,各国指南对其在高血压治疗中的应用给出了不同建议。指南对β受体阻滞剂的推荐有何不同?2004年英国NI

美国又出一新高血压指南 到底该信谁?

“Our goal was to create a very simple document, we wanted to make the message very simple for physicians.”虽然呢,翻旧帐不是什么好习惯,但是既然新指南来了,所以不得不旧话重提下。是的,一年半前,2014年美国成人高血压治疗指南(JNC 8)的lead author就是像上面这段这么说的

6种你不知道的“特殊型”高血压

高血压通常指在安静状态下、坐位右上臂血压大于或等于140/90毫米汞柱。随着监测手段的不断更新,现已证实:在医院中偶尔测得的基础的、静态的血压并不能全面反映患者在日常生活中的真实血压水平。随着24小时动态血压监测的日益普及,医生们发现了6种常见但容易被忽视的特殊类型高血压。白大衣高血压在研究高血压的过程中,人们发现部分患者仅在诊室内测量的血压升高,而在诊室以外的地方血压正常,这一现象被称为“白大衣

高血压、使用呋塞米,竟与原发性甲旁亢相关?

一项新研究发现,很多老年白人女性的原发性甲状旁腺机能亢进的风险明显升高,与高血压及使用呋塞米密切相关。 来自美国的研究者评估了护士健康研究中75600例女护士的数据,从1986年随访至2008年,基线时无原发性甲状旁腺机能亢进,目的是确定高血压病史、使用某些抗高血压药物是否可升高原发性甲状旁腺机能亢进的风险。 在高血压人群中,在超过70万人-年的随访中,共计出现222例原发性甲状旁腺机能亢进,